Day One Biopharmaceuticals Inc (NASDAQ:DAWN) traded at $8.07 at close of the session on Monday, March 10 and made a downward move of -6.92% on its previous day’s price.
Day One Biopharmaceuticals Inc has a market cap of $817.93 million and is expected to release its quarterly earnings report in April.
Analysts tracking the company’s growth have also given it a consensus growth in revenue estimated at 31.82M, with a low of 25M and a high of 34.75M. According to analyst consensus estimates figures, the company’s yearly revenue forecast for current year is expected to hit 164.11M, or 25.12% up from figures reported last year.
On the other hand, looking at the outlook for the DAWN stock, short term indicators assign the stock an average of 100% Sell, while medium term indicators assign it an average of 100% Sell.
Based on estimates by 5 analysts, where scores have ranged from 1.00 for a strong buy to 5.00 for a strong sell, 0 have rated the Day One Biopharmaceuticals Inc (DAWN) stock as a Hold, while 5 rate it as a Buy. 0 analyst(s) rate it as overweight while 0 of them rated it as underweight, whereas 0 suggest the stock as a Sell. The stock has an overall rating of Buy and investors could take advantage and scoop up stock of the company.
Looking further, we note the current price level is -24.41% off its SMA20 and -31.05% from its 50-day simple moving average. The RSI (14) is pointing at 29.09 while the volatility over the past week is 6.77% and jumps to 5.93% over the past one month. The beta value is -1.35, while the average true range (ATR) is currently pointing at 0.67. The average price target for the stock over the next 12 months is $40, with the estimates having a low of $24 and a high of $45. These price ends are -197.4% and -457.62% off the current price level respectively, although investors could be excited at the prospect of a -395.66% if the DAWN share price touches on the median price of $40.
